Blockbuster drug patent expiration, advances in enabling technology, and the emergence of personalized medicine for prostate cancer treatment create a landscape worth examining.
Published in Nature Biotechnology
Authors: Michael Casasanta, PhD , Nicholas Frame, PhD & Oded Ben-Joseph, PhD, MBA
Abstract:
• Exploring strategic decision-making within the prostate cancer market; a look at the intersection of innovation and opportunism
• We explore how leading companies are adapting to maintain and grow market leadership in an environment of patent expiry, technological advancement, and regulatory landscape shifts
• There has been a flurry of transactional activity in the space among medical device and pharmaceutical companies in recent years
Outcome Capital has been named Life Sciences Review’s exclusive recipient of the “Top Life Sciences Advisory and Strategic Investment Banking Solutions 2026” award, recognizing its unique approach to helping life sciences companies move innovations from development to commercialization. The firm combines scientific, clinical, operational, and financial expertise to support emerging and growth-stage companies with fundraising, […]
Read More
Outcome Capital Life Science Market Pulse July 2026 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?